A Real Life Evaluation of the Performance of a Large Volume Nebulizer
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Continuous albuterol has become the standard of care for patients in status asthmaticus. We have previously performed an in-vitro study comparing 4 different brands of continuous nebulizers. We now want to compare the in-vitro with the in-vivo performance of the brand we use. we hypothesize that there will be no difference between in-vivo and in-vitro results.
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | A Real Life Evaluation of the Performance of a Large Volume Nebulizer |
- Nebulizer solution output [ Time Frame: every 2 hours for first 6 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | March 2008 |
| Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
There will be no intervention to the patients. Nebulizers will be used as per current policies and procedures. They will only be marked on the outside at the water level every 2 hours for the first 6 hours. Once ready to be discarded will be collected for laboratory testing Once in the laboratory, nebulizers will be weight on a precision scale without liquid, then they will be filled with normal saline to the first mark (6th hour) and re-weight. The nebulizers will be filled to next mark and re-weight until 200 mls. of total volume are achieved. Solution output will be calculated as the weight difference between the 2 hour periods.
Eligibility| Ages Eligible for Study: | up to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Pediatric patients admitted to the Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.
Inclusion Criteria:
- Pediatric patients admitted to Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.
Exclusion Criteria:
- Patients requiring invasive or non-invasive ventilation.
Contacts and Locations| Contact: Ariel Berlinski, M.D. | 501-364-1006 | berlinskiariel@uams.edu |
| United States, Arkansas | |
| Arkansas Children's Hospital | Recruiting |
| Little Rock, Arkansas, United States, 72202 | |
| Contact: Ariel Berlinski, M.D. 501-364-1006 berlinskiariel@uams.edu | |
| Principal Investigator: Ariel Berlinski, M.D. | |
| Sub-Investigator: Randy Willis, R.R.T. | |
| Principal Investigator: | Ariel Berlinski, M.D. | University of Arkansas |
More Information
No publications provided
| Responsible Party: | Ariel Berlinski, University of Arkansas for Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00632112 History of Changes |
| Other Study ID Numbers: | 98551 |
| Study First Received: | February 29, 2008 |
| Last Updated: | June 3, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Arkansas Children's Hospital Research Institute:
|
large volume nebulizer |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013